RPL17 and melanoma: The melanoma treatment-associated sensitivity analysis conducted on the low- and high-risk subgroups indicates that the low-risk subgroup exhibited more positive responses to CTLA4 and PD-1 therapy than the high-risk subgroup (Fig. 6D).